| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $64,160,790 ) (Continued on the next page) |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA283395 | Mechanisms of Toxicity Induced by EWS/FLI1 Overdose in Ewing Sarcoma | 000 | 4 | NIH | 5/1/2026 | $713,593 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA303137 | Protein O' Mannosylation as a therapeutic vulnerability in KIAA1549-BRAF-driven pediatric low-grade glioma | 000 | 1 | NIH | 6/9/2026 | $721,653 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | UH3NS132127 | Single Molecule Detection of L1 Insertions and Intermediates | 000 | 4 | NIH | 3/24/2026 | $698,829 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA262462 | Synthetic lethalities to cell cycle disruption in glioma | 000 | 5 | NIH | 6/11/2026 | $673,491 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA271605 | Cell lineage as an indicator of immune response in neuroblastoma | 000 | 5 | NIH | 6/1/2026 | $405,378 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA259621 | Elucidating the molecular and cellular mechanisms of immune evasion in pancreatic cancer | 000 | 5 | NIH | 6/5/2026 | $230,972 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA284279 | Evaluating METTL1-mediated m7G tRNA methylation as a novel dependency in alveolar rhadomyosarcoma | 000 | 4 | NIH | 3/3/2026 | $103,486 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA259200 | Genomic and Genomic Variation in Prostate Cancer | 000 | 5 | NIH | 6/9/2026 | $961,324 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA304214 | Therapeutic Strategies to Prevent Small Cell Lung Cancer Histological Transformation | 000 | 2 | NIH | 6/11/2026 | $137,281 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA269574 | Promoting Resilience in Early Survivorship among Adolescents and Young Adults with Cancer | 000 | 5 | NIH | 2/27/2026 | $788,243 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279391 | Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy | 001 | 3 | NIH | 4/16/2026 | $72,700 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279391 | Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy | 000 | 3 | NIH | 1/15/2026 | $654,298 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK142741 | Structural Basis of Thermogenic Mitochondrial Respiratory Complexes Assembly | 000 | 2 | NIH | 4/6/2026 | $813,511 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK140171 | Cellular and Biochemical Pathways of Adipose Metabolism and Thermogenesis | 000 | 2 | NIH | 4/28/2026 | $844,198 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA284254 | Defining Therapeutically Targetable Regulators of Tumor-Intrinsic Immune Suppression in Glioblastoma | 001 | 4 | NIH | 4/16/2026 | $10,313 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA284254 | Defining Therapeutically Targetable Regulators of Tumor-Intrinsic Immune Suppression in Glioblastoma | 000 | 4 | NIH | 1/13/2026 | $92,813 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R35GM158220 | Empowering NMR Utilization in Mechanistic Biology: Extending Size Limits and Catalyzing Automation | 000 | 2 | NIH | 5/13/2026 | $489,500 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA097098 | Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer | 000 | 22 | NIH | 3/30/2026 | $454,678 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA269285 | Cyclin C-CDK8/19 kinases in development and in cancer | 000 | 5 | NIH | 4/17/2026 | $525,969 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA286537 | Mechanism and functional consequences of dietary lipids in lineage specification and tumor growth in oncohistone gliomas | 001 | 3 | NIH | 4/13/2026 | $702,458 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F31CA301844 | Unraveling the Mechanisms of Neoantigen Vaccine-Induced Epitope Spreading | 000 | 2 | NIH | 6/10/2026 | $37,114 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA155010 | Personal tumor neoantigens for immunity against chronic lymphocytic leukemia | 001 | 15 | NIH | 4/16/2026 | $75,920 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA155010 | Personal tumor neoantigens for immunity against chronic lymphocytic leukemia | 000 | 15 | NIH | 1/27/2026 | $683,283 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK082889 | Transcriptional control and enhancer recruitment in mouse and human intestinal secretory differentiation | 000 | 14 | NIH | 2/26/2026 | $372,621 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA300092 | Mapping the epigenetic dynamics of prostate cancer progression: integrating liquid biopsies and single-cell epigenomics for early detection of lineage plasticity and clinical decision-making | 000 | 2 | NIH | 3/23/2026 | $406,450 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA300092 | Mapping the epigenetic dynamics of prostate cancer progression: integrating liquid biopsies and single-cell epigenomics for early detection of lineage plasticity and clinical decision-making | 001 | 2 | NIH | 4/3/2026 | $201,524 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | UG1CA233180 | NCTN Lead Academic Participating Site at Dana-Farber/Harvard Cancer Consortium | 000 | 7 | NIH | 4/1/2026 | $997,843 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK078081 | Metabolic crosstalks in regulation of beta-cell stress response and adaptation | 000 | 14 | NIH | 3/2/2026 | $488,374 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279221 | Dissecting Integrated Cellular Programs Promoting Platinum Resistance and Progression in Bladder Cancer | 000 | 3 | NIH | 3/27/2026 | $712,559 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA296230 | Targeting the CDK4/6 pathway in MiT/TFE-translocation renal cell carcinoma | 001 | 2 | NIH | 4/16/2026 | $20,800 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA296230 | Targeting the CDK4/6 pathway in MiT/TFE-translocation renal cell carcinoma | 000 | 2 | NIH | 1/7/2026 | $187,204 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA265928 | A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies | 000 | 5 | NIH | 3/3/2026 | $674,251 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA279891 | Epigenetic regulators define a dynamic chromatin landscape in NUP98-rearranged leukemia | 000 | 3 | NIH | 2/27/2026 | $215,179 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA269990 | Mechanisms by which LSD1 Promotes Neuroendocrine Differentiation and Small Cell Lung Cancer | 001 | 4 | NIH | 4/16/2026 | $45,953 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA269990 | Mechanisms by which LSD1 Promotes Neuroendocrine Differentiation and Small Cell Lung Cancer | 000 | 4 | NIH | 1/16/2026 | $413,593 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AI179839 | High-throughput single-cell RNA sequencing of bacteria to uncover cell states involved in pathogenesis | 000 | 3 | NIH | 4/6/2026 | $813,272 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R00CA266921 | SESORRS endoscopy for the staging and evaluation of colorectal cancer | 001 | 5 | NIH | 4/16/2026 | $24,900 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R00CA266921 | SESORRS endoscopy for the staging and evaluation of colorectal cancer | 000 | 5 | NIH | 1/9/2026 | $224,099 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01HL171973 | Molecular mechanisms of splicing dependency in cohesin-mutant myelodysplasia | 000 | 3 | NIH | 2/9/2026 | $445,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA221874 | Comprehensive minimal residual disease tracking in cancer | 001 | 6 | NIH | 4/16/2026 | $44,264 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA221874 | Comprehensive minimal residual disease tracking in cancer | 000 | 6 | NIH | 12/15/2025 | $398,378 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01HL052725 | Molecular Pathogenesis of Fanconi Anemia | 000 | 31 | NIH | 2/12/2026 | $445,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01AI165442 | Identification of Metabolic and Immune Deficits in the Aged Population and Their Restoration to Achieve Youthful Anti-Influenza Vaccine Responsiveness | 000 | 5 | NIH | 11/26/2025 | $1,164,461 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01HG013083 | Integrative modelling of single-cell data to elucidate the genetic architecture of complex disease | 000 | 3 | NIH | 5/11/2026 | $502,740 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA274706 | SIRT1 Regulates RNA Stability to Promote Breast Cancer | 000 | 5 | NIH | 5/12/2026 | $100,008 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA278980 | Dissecting Convergent Somatic and Germline Alterations that Mediate the Origins and Evolution of Kidney Cancer | 001 | 3 | NIH | 4/16/2026 | $67,440 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA278980 | Dissecting Convergent Somatic and Germline Alterations that Mediate the Origins and Evolution of Kidney Cancer | 000 | 3 | NIH | 2/24/2026 | $606,976 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01GM152499 | Survival Data Analysis using general censoring-free incident rate | 000 | 3 | NIH | 3/26/2026 | $331,175 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P01CA306849 | Precision Interception for MGUS/SMM | 000 | 1 | NIH | 5/26/2026 | $2,498,737 |
|
